VEGF siRNA Delivery by a Cancer-Specific Cell-Penetrating Peptide (2018)
Sequence: RAGLPFQVGRLLRRLLR
| Experiment Id | EXP000929 |
|---|---|
| Paper | VEGF siRNA Delivery by a Cancer-Specific Cell-Penetrating Peptide |
| Peptide | BR2 (cancer-specific CPP) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | N/P=8 (1 h transfection); siRNA amount not explicitly stated for silencing assay |
| Rna Concentration | not reported (readout at 48 h) |
| Mixing Ratio | N/P = 8 |
| Formulation Format | noncovalent CPP-siRNA complexes (electrostatic; N/P ratio) |
| Formulation Components | BR2 peptide + siGFP |
| Size Nm | 200.00 |
| Zeta Mv | 8.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | GFP-expressing HeLa and GFP-expressing NIH3T3 |
| Animal Model | |
| Administration Route | |
| Output Type | in vitro knockdown (GFP fluorescence/ELISA + qRT-PCR) |
| Output Value | HeLa: GFP fluorescence down 57.9% and GFP mRNA down 60.6%; NIH3T3: GFP fluorescence down 45.6% and GFP mRNA down 52.5% |
| Output Units | |
| Output Notes | GFP silencing measured 48 h post-transfection; confocal microscopy shown. |
| Toxicity Notes | No major cytotoxicity emphasized for BR2-siRNA complexes. |
| Curation Notes |